BLA 125291 · Genzyme
Lumizyme
Alglucosidase Alfa · Iv (Infusion) · Hydrolytic Lysosomal Glycogen-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
May 24, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
30
6 Phase 3, 2 recruiting
FAERS reports
2,436
921 serious, 118 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, IMMUNE-MEDIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, IMMUNE-MEDIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE See full prescribing information for complete boxed warning. Hypersensitivity Reactions Including Anaphylaxis Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate LUMIZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue LUMIZYME and immediately initiate appropriate medical treatment, including use of epinephrine. ( 5.1 ) Immune-Mediated Reactions Immune-mediated reactions presenting as...
What it is approved for
From the label in effect Jan 10, 2025.
LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency). LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency). ( 1 )
Mechanism: Pompe disease (acid maltase deficiency, glycogen storage disease type II, GSD II, glycogenosis type II) is an inherited disorder of glycogen metabolism caused by the absence or marked deficiency of the lysosomal enzyme GAA. Alglucosidase alfa provides an exogenous source of GAA. Binding to mannose-6-phosphate receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalized and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity. It then exerts enzymatic activity in...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 1, 2014 Supplement 136 · Efficacy · priority review LabelReviewLetter
- May 24, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- LUMIZYME · ALGLUCOSIDASE ALFA 5MG/ML · POWDER, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alglucosidase Alfa" as an intervention, any sponsor and status, largest first.
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT03729362 · 125 participants · Start Dec 4, 2018 · Primary completion Dec 15, 2020
Drug: Cipaglucosidase Alfa; Miglustat and 2 more · For: Pompe Disease (Late-onset)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Irvine, California · 73 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01526785 · 113 participants · Start Mar 2012 · Primary completion Dec 2014
Drug: Alglucosidase alfa · For: Pompe Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 51 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02782741 · 101 participants · Start Nov 2, 2016 · Primary completion Mar 19, 2020
Drug: Avalglucosidase alfa (GZ402666); Alglucosidase alfa (GZ419829) · For: Glycogen Storage Disease Type II;Pompe's Disease
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 69 sites in all
- A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe DiseasePivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00158600 · 90 participants · Start Sep 2005 · Primary completion Sep 2007
Drug: alglucosidase alfa; Placebo · For: Pompe Disease (Late-onset); Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease and 1 more
Sites: Beverly Hills, California; Washington D.C., District of Columbia; St Louis, Missouri · 8 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00455195 · 81 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: alglucosidase alfa · For: Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD-II); Glycogenesis Type II and 1 more
Sites: Anchorage, Alaska; Phoenix, Arizona; Beverly Hills, California · 31 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT04676373 · 41 participants · Start Mar 10, 2021 · Primary completion Jul 25, 2024
Drug: ALGLUCOSIDASE ALFA · For: Pompe's Disease
Sites: China, China
- Drug-drug Interaction StudyCompleted
Amicus TherapeuticsIndustry
NCT01380743 · 25 participants · Start Oct 31, 2011 · Primary completion Jan 4, 2013
Drug: duvoglustat; rhGAA · For: Pompe Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Orange, California · 15 sites in all
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.Completed
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01898364 · 24 participants · Start Aug 19, 2013 · Primary completion Feb 25, 2015
Drug: GZ402666 · For: Pompe Disease; Glycogen Storage Disease Type II (GSD II); Acid Maltase Deficiency
Sites: Phoenix, Arizona; Jacksonville, Florida; Kansas City, Kansas · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- inappropriate schedule of product administration219
- pyrexia179
- off label use153
- dyspnoea141
- malaise105
- fatigue100
- pneumonia100
- fall95
- drug specific antibody present89
- urticaria87
- infusion related reaction83
- rash83
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 24 |
| 2012 | 43 |
| 2013 | 153 |
| 2014 | 210 |
| 2015 | 181 |
| 2016 | 143 |
| 2017 | 148 |
| 2018 | 146 |
| 2019 | 182 |
| 2020 | 121 |
| 2021 | 225 |
| 2022 | 263 |
| 2023 | 210 |
| 2024 | 150 |
| 2025 | 130 |
| 2026 | 102 |
Recalls
1 FDA enforcement reports for this application.
Dec 8, 2015 · Class III · Terminated
Labeling: Incorrect or Missing Lot and/or Exp Date
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lumizyme (Alglucosidase Alfa)
2024 spending
$13.2M
Beneficiaries
17
206 claims
Per beneficiary
$778,063
$967.39 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,712,903 |
| 2021 | $49,935,206 |
| 2022 | $29,852,277 |
| 2023 | $18,626,215 |
| 2024 | $13,227,075 |
Part B: Lumizyme (Alglucosidase Alfa) · HCPCS J0221
2024 spending
$17.1M
Beneficiaries
31
429 claims
Per beneficiary
$552,042
2024 ASP limit $199.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $62,106,435 |
| 2021 | $61,675,530 |
| 2022 | $41,371,331 |
| 2023 | $25,682,601 |
| 2024 | $17,113,296 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA, Hsu RH, Fang CY, et al. · Front Immunol 2024 · Clinical Trial, Research Support, Non-U.S. Gov't
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, et al. · J Patient Rep Outcomes 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, et al. · Lancet Neurol 2021 · Multicenter Study, Randomized Controlled Trial
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, et al. · Lancet Neurol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, et al. · JAMA Neurol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, et al. · J Neurol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.